查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566753

疼痛管理药物市场：依药物类别、适应症、疼痛类型：2024-2033 年全球机会分析与产业预测

Pain Management Drugs Market By Drug Class , By Indication By Pain Type : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3个工作天内

价格
简介目录

疼痛管理药物市场

2023年疼痛管理药物市场价值为726亿美元，预计2024年至2033年复合年增长率为4.2%，到2033年达到1096亿美元。

疼痛管理药物是用于缓解疼痛的药物，疼痛范围从中度不适到重度疼痛。疼痛管理药物配方由不同的药物类别组成，例如鸦片类药物、抗忧郁症和乙酰胺酚。这些药物针对不同类型的疼痛，包括肌肉骨骼疼痛、神经病变和发炎。疼痛管理药物发挥作用的机制多种多样，包括减少发炎、抑制神经系统中的疼痛信号以及改变大脑化学物质以调节疼痛感知。

文明病和中风、心臟病、第二型糖尿病和癌症等慢性疾病的增加正在推动疼痛管理药物市场的发展。此外，药物製剂和给药方法的进步，例如减少剂量数量的缓释性，正在推动对药物的需求，以提高患者的依从性和治疗结果。最近，对奈米治疗药物的研究一直是市场的趋势，因为奈米颗粒有望能够精确定位目标并在低剂量下提供长期疗效。

然而，疼痛治疗药物具有严重的副作用，如心血管事件、消化道出血、镇静、肾功能损害和呼吸抑制等，这限制了其消费量，并对市场扩张构成挑战。为了消除传统药物的危险，人们正在考虑副作用较少的天然替代品。例如，卡痛叶（Kratom）是一种从帽柱树（Mitragyna spiosa）中提取的草药物质，被用作阿片类药物的替代品。卡痛药已被证明在缓解纤维肌痛、关节炎和神经病变疼痛等慢性疼痛方面非常有效。

分部审查

疼痛管理药物市场按药物类别、适应症、疼痛类型和地区细分。依药物类别划分，市场分为非类固醇消炎剂、麻醉剂、抗惊厥药、抗偏头痛药、抗忧郁症、鸦片类药物和非麻醉性止痛药。依适应症分为关节痛、神经病变疼痛、癌症疼痛、慢性背痛、术后疼痛、偏头痛、纤维肌痛、肌肉拉伤/拉伤、骨折、急性阑尾炎等。依疼痛类型分为慢性疼痛和急性疼痛。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按药物类别划分，阿片类药物预计将在预测期内主导市场。

有迹象表明，到 2033 年，术后疼痛领域预计将成为最大股东。

按疼痛类型划分，预计慢性疼痛细分市场将在预测期内引领市场。

按地区划分，预计到 2033 年，北美地区的收益将最高。

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章疼痛管理药物市场：依药物类别

  • 市场概况
  • 非类固醇消炎剂
  • 麻醉剂
  • 抗惊厥药
  • 抗偏头痛药
  • 抗忧郁症
  • 阿片类药物
  • 非麻醉性止痛药

第五章疼痛管理药物市场：依适应症分类

  • 市场概况
  • 关节痛
  • 神经病变疼痛
  • 癌症痛
  • 慢性腰痛
  • 术后疼痛
  • 偏头痛
  • 纤维肌痛
  • 肌肉扭伤/拉伤
  • 断裂
  • 急性阑尾炎
  • 其他的

第六章疼痛管理药物市场：依疼痛类型

  • 市场概况
  • 慢性疼痛
  • 急性疼痛

第七章疼痛管理药物市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国疼痛管理药物市场
    • 加拿大疼痛管理药物市场
    • 墨西哥止痛药物市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国疼痛管理药物市场
    • 法国止痛药市场
    • 英国疼痛管理药物市场
    • 义大利疼痛管理药物市场
    • 西班牙止痛药市场
    • 其他欧洲疼痛管理药物市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本疼痛管理药物市场
    • 中国疼痛管理药物市场
    • 印度止痛药市场
    • 澳洲疼痛管理药物市场
    • 韩国疼痛管理药物市场
    • 其他亚太地区止痛药市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西疼痛管理药物市场
    • 沙乌地阿拉伯疼痛管理药物市场
    • 南非疼痛管理药物市场
    • 其他拉丁美洲/中东/非洲疼痛管理药物市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Novartis AG
  • Eli Lilly And Company
  • Abbott Laboratories
  • Endo Health Solutions, Inc.
  • Purdue Pharma LP
  • Pfizer, Inc.
  • Viatris Inc.
  • Merck And Co. Inc.
  • Johnson And Johnson
  • GlaxoSmithKline Plc
简介目录
Product Code: A00309

Pain Management Drugs Market

The pain management drugs market was valued at $72.6 billion in 2023 and is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033.

A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort to severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining to the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry to modulate the perception of pain.

Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated to possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.

However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. To eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal to no side-effects. For instance, Kratom, a herbal substance obtained from the Mitragyna speciosa tree, is being utilized as an alternative to opioid drugs. Kratom medications have proved to be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.

Segment Review

The pain management drugs market is segmented into drug class, indication, pain type, and region. On the basis of drug class, the market is divided into NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated into chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug class, the opioids segment is expected to dominate the market during the forecast period.

As per indication, the postoperative pain segment is predicted to be the highest shareholder by 2033.

By pain type, the chronic pain segment is anticipated to lead the market during the forecast period.

Region wise, North America is projected to be the highest revenue generator by 2033.

Competition Analysis

The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viatris Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Muscle Sprain/Strain
  • Bone Fracture
  • Acute Appendicitis
  • Others

By Pain Type

  • Chronic Pain
  • Acute Pain

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Eli Lilly & Company
    • Abbott Laboratories
    • Endo Health Solutions, Inc.
    • Purdue Pharma L.P.
    • Pfizer, Inc.
    • Viatris Inc.
    • Merck & Co. Inc.
    • Johnson & Johnson
    • GlaxoSmithKline Plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Class
  • 4.2. NSAIDs
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Anesthetics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Anticonvulsants
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Anti-migraine Agents
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Antidepressants
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country
  • 4.7. Opioids
    • 4.7.1. Key Market Trends, Growth Factors and Opportunities
    • 4.7.2. Market Size and Forecast, By Region
    • 4.7.3. Market Share Analysis, By Country
  • 4.8. Nonnarcotic Analgesics
    • 4.8.1. Key Market Trends, Growth Factors and Opportunities
    • 4.8.2. Market Size and Forecast, By Region
    • 4.8.3. Market Share Analysis, By Country

CHAPTER 5: PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Arthritic Pain
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Neuropathic Pain
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Cancer Pain
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Chronic Back Pain
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Postoperative Pain
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Migraine
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country
  • 5.8. Fibromyalgia
    • 5.8.1. Key Market Trends, Growth Factors and Opportunities
    • 5.8.2. Market Size and Forecast, By Region
    • 5.8.3. Market Share Analysis, By Country
  • 5.9. Muscle Sprain/Strain
    • 5.9.1. Key Market Trends, Growth Factors and Opportunities
    • 5.9.2. Market Size and Forecast, By Region
    • 5.9.3. Market Share Analysis, By Country
  • 5.10. Bone Fracture
    • 5.10.1. Key Market Trends, Growth Factors and Opportunities
    • 5.10.2. Market Size and Forecast, By Region
    • 5.10.3. Market Share Analysis, By Country
  • 5.11. Acute Appendicitis
    • 5.11.1. Key Market Trends, Growth Factors and Opportunities
    • 5.11.2. Market Size and Forecast, By Region
    • 5.11.3. Market Share Analysis, By Country
  • 5.12. Others
    • 5.12.1. Key Market Trends, Growth Factors and Opportunities
    • 5.12.2. Market Size and Forecast, By Region
    • 5.12.3. Market Share Analysis, By Country

CHAPTER 6: PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Pain Type
  • 6.2. Chronic Pain
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Acute Pain
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Drug Class
    • 7.2.3. Market Size and Forecast, By Indication
    • 7.2.4. Market Size and Forecast, By Pain Type
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Pain Management Drugs Market
      • 7.2.6.1. Market Size and Forecast, By Drug Class
      • 7.2.6.2. Market Size and Forecast, By Indication
      • 7.2.6.3. Market Size and Forecast, By Pain Type
    • 7.2.7. Canada Pain Management Drugs Market
      • 7.2.7.1. Market Size and Forecast, By Drug Class
      • 7.2.7.2. Market Size and Forecast, By Indication
      • 7.2.7.3. Market Size and Forecast, By Pain Type
    • 7.2.8. Mexico Pain Management Drugs Market
      • 7.2.8.1. Market Size and Forecast, By Drug Class
      • 7.2.8.2. Market Size and Forecast, By Indication
      • 7.2.8.3. Market Size and Forecast, By Pain Type
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Drug Class
    • 7.3.3. Market Size and Forecast, By Indication
    • 7.3.4. Market Size and Forecast, By Pain Type
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Pain Management Drugs Market
      • 7.3.6.1. Market Size and Forecast, By Drug Class
      • 7.3.6.2. Market Size and Forecast, By Indication
      • 7.3.6.3. Market Size and Forecast, By Pain Type
    • 7.3.7. France Pain Management Drugs Market
      • 7.3.7.1. Market Size and Forecast, By Drug Class
      • 7.3.7.2. Market Size and Forecast, By Indication
      • 7.3.7.3. Market Size and Forecast, By Pain Type
    • 7.3.8. UK Pain Management Drugs Market
      • 7.3.8.1. Market Size and Forecast, By Drug Class
      • 7.3.8.2. Market Size and Forecast, By Indication
      • 7.3.8.3. Market Size and Forecast, By Pain Type
    • 7.3.9. Italy Pain Management Drugs Market
      • 7.3.9.1. Market Size and Forecast, By Drug Class
      • 7.3.9.2. Market Size and Forecast, By Indication
      • 7.3.9.3. Market Size and Forecast, By Pain Type
    • 7.3.10. Spain Pain Management Drugs Market
      • 7.3.10.1. Market Size and Forecast, By Drug Class
      • 7.3.10.2. Market Size and Forecast, By Indication
      • 7.3.10.3. Market Size and Forecast, By Pain Type
    • 7.3.11. Rest of Europe Pain Management Drugs Market
      • 7.3.11.1. Market Size and Forecast, By Drug Class
      • 7.3.11.2. Market Size and Forecast, By Indication
      • 7.3.11.3. Market Size and Forecast, By Pain Type
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Drug Class
    • 7.4.3. Market Size and Forecast, By Indication
    • 7.4.4. Market Size and Forecast, By Pain Type
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Pain Management Drugs Market
      • 7.4.6.1. Market Size and Forecast, By Drug Class
      • 7.4.6.2. Market Size and Forecast, By Indication
      • 7.4.6.3. Market Size and Forecast, By Pain Type
    • 7.4.7. China Pain Management Drugs Market
      • 7.4.7.1. Market Size and Forecast, By Drug Class
      • 7.4.7.2. Market Size and Forecast, By Indication
      • 7.4.7.3. Market Size and Forecast, By Pain Type
    • 7.4.8. India Pain Management Drugs Market
      • 7.4.8.1. Market Size and Forecast, By Drug Class
      • 7.4.8.2. Market Size and Forecast, By Indication
      • 7.4.8.3. Market Size and Forecast, By Pain Type
    • 7.4.9. Australia Pain Management Drugs Market
      • 7.4.9.1. Market Size and Forecast, By Drug Class
      • 7.4.9.2. Market Size and Forecast, By Indication
      • 7.4.9.3. Market Size and Forecast, By Pain Type
    • 7.4.10. South Korea Pain Management Drugs Market
      • 7.4.10.1. Market Size and Forecast, By Drug Class
      • 7.4.10.2. Market Size and Forecast, By Indication
      • 7.4.10.3. Market Size and Forecast, By Pain Type
    • 7.4.11. Rest of Asia-Pacific Pain Management Drugs Market
      • 7.4.11.1. Market Size and Forecast, By Drug Class
      • 7.4.11.2. Market Size and Forecast, By Indication
      • 7.4.11.3. Market Size and Forecast, By Pain Type
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Drug Class
    • 7.5.3. Market Size and Forecast, By Indication
    • 7.5.4. Market Size and Forecast, By Pain Type
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Pain Management Drugs Market
      • 7.5.6.1. Market Size and Forecast, By Drug Class
      • 7.5.6.2. Market Size and Forecast, By Indication
      • 7.5.6.3. Market Size and Forecast, By Pain Type
    • 7.5.7. Saudi Arabia Pain Management Drugs Market
      • 7.5.7.1. Market Size and Forecast, By Drug Class
      • 7.5.7.2. Market Size and Forecast, By Indication
      • 7.5.7.3. Market Size and Forecast, By Pain Type
    • 7.5.8. South Africa Pain Management Drugs Market
      • 7.5.8.1. Market Size and Forecast, By Drug Class
      • 7.5.8.2. Market Size and Forecast, By Indication
      • 7.5.8.3. Market Size and Forecast, By Pain Type
    • 7.5.9. Rest of LAMEA Pain Management Drugs Market
      • 7.5.9.1. Market Size and Forecast, By Drug Class
      • 7.5.9.2. Market Size and Forecast, By Indication
      • 7.5.9.3. Market Size and Forecast, By Pain Type

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Eli Lilly And Company
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Abbott Laboratories
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Endo Health Solutions, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Purdue Pharma L.P.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Pfizer, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Viatris Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Merck And Co. Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Johnson And Johnson
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. GlaxoSmithKline Plc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments